ABSTRACT
Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential effector of B-cell receptor (BCR) signaling. Chronic activation of BTK-mediated BCR signaling is a hallmark of many hematological malignancies, which makes it an attractive therapeutic target. Pharmacological inhibition of BTK enzymatic function is now a well-proven strategy for the treatment of patients with these malignancies. We report the discovery and characterization of NX-2127, a BTK degrader with concomitant immunomodulatory activity. By design, NX-2127 mediates the degradation of transcription factors IKZF1 and IKZF3 through molecular glue interactions with the cereblon E3 ubiquitin ligase complex. NX-2127 degrades common BTK resistance mutants, including BTKC481S. NX-2127 is orally bioavailable, exhibits in vivo degradation across species, and demonstrates efficacy in preclinical oncology models. NX-2127 has advanced into first-in-human clinical trials and achieves deep and sustained degradation of BTK following daily oral dosing at 100 mg.
Subject(s)
Protein Kinase Inhibitors , Protein-Tyrosine Kinases , Humans , Agammaglobulinaemia Tyrosine Kinase , Protein Kinase Inhibitors/adverse effects , Signal TransductionABSTRACT
We recently reported on the discovery of AMG 232, a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. AMG 232 is being evaluated in human clinical trials for cancer. Continued exploration of the N-alkyl substituent of this series, in an effort to optimize interactions with the MDM2 glycine-58 shelf region, led to the discovery of sulfonamides such as compounds 31 and 38 that have similar potency, hepatocyte stability and rat pharmacokinetic properties to AMG 232.
Subject(s)
Acetates/pharmacology , Drug Discovery , Piperidones/pharmacology , Proto-Oncogene Proteins c-mdm2/antagonists & inhibitors , Sulfonamides/chemistry , Tumor Suppressor Protein p53/antagonists & inhibitors , Acetates/chemistry , Animals , Crystallography, X-Ray , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Models, Molecular , Molecular Conformation , Piperidones/chemistry , Protein Binding/drug effects , Proto-Oncogene Proteins c-mdm2/chemistry , Rats , Structure-Activity Relationship , Tumor Suppressor Protein p53/chemistryABSTRACT
We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutilized interaction in a shallow cleft on the MDM2 surface, led to the discovery of a one-carbon tethered sulfone which gave rise to substantial improvements in biochemical and cellular potency. Further investigation produced AMG 232 (2), which is currently being evaluated in human clinical trials for the treatment of cancer. Compound 2 is an extremely potent MDM2 inhibitor (SPR KD = 0.045 nM, SJSA-1 EdU IC50 = 9.1 nM), with remarkable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft model (ED50 = 9.1 mg/kg).
Subject(s)
Acetates/pharmacology , Antineoplastic Agents/pharmacology , Piperidones/pharmacology , Proto-Oncogene Proteins c-mdm2/antagonists & inhibitors , Tumor Suppressor Protein p53/antagonists & inhibitors , Acetates/chemistry , Administration, Oral , Antineoplastic Agents/chemistry , Biological Availability , Crystallography, X-Ray , Drug Discovery , Humans , Piperidones/chemistry , Protein ConformationABSTRACT
The eukaryotic initiation factor 4E (eIF4E) plays a central role in the initiation of gene translation and subsequent protein synthesis by binding the 5' terminal mRNA cap structure. We designed and synthesized a series of novel compounds that display potent binding affinity against eIF4E despite their lack of a ribose moiety, phosphate, and positive charge as present in m7-GMP. The biochemical activity of compound 33 is 95 nM for eIF4E in an SPA binding assay. More importantly, the compound has an IC(50) of 2.5 µM for inhibiting cap-dependent mRNA translation in a rabbit reticular cell extract assay (RRL-IVT). This series of potent, truncated analogues could serve as a promising new starting point toward the design of neutral eIF4E inhibitors with physicochemical properties suitable for cellular activity assessment.
Subject(s)
Eukaryotic Initiation Factor-4E/metabolism , Guanine/analogs & derivatives , Guanosine Monophosphate/analogs & derivatives , Guanosine Monophosphate/pharmacology , Organophosphonates/chemical synthesis , RNA Caps/metabolism , Animals , Crystallography, X-Ray , Drug Design , Eukaryotic Initiation Factor-4E/chemistry , Guanine/chemical synthesis , Guanine/pharmacology , Guanosine Monophosphate/chemical synthesis , Humans , Inhibitory Concentration 50 , Models, Molecular , Organophosphonates/pharmacology , Phosphorous Acids , Protein Biosynthesis/drug effects , RNA Caps/chemistry , Rabbits , Reticulocytes/drug effects , Reticulocytes/metabolism , Structure-Activity RelationshipABSTRACT
A series of spiropiperidine carbazoles were synthesized and evaluated as MCHR2 antagonists using a FLIPR assay. The pharmacokinetic properties of selected compounds have also been studied. This effort led to the discovery of potent and specific MCHR2 antagonists. Compound 38 demonstrated good pharmacokinetic properties across rat, beagle dog and rhesus monkey and had a favorable selectivity profile against a number of other receptors. These MCHR2 antagonists are considered appropriate tool compounds for study of the function of MCHR2 in vivo.
Subject(s)
Carbazoles/chemistry , Chemistry, Pharmaceutical/methods , Piperidines/chemistry , Receptors, G-Protein-Coupled/antagonists & inhibitors , Receptors, Pituitary Hormone/antagonists & inhibitors , Animals , CHO Cells , Cell Line , Cricetinae , Dogs , Drug Design , Humans , Inhibitory Concentration 50 , Macaca mulatta , Models, Chemical , Rats , Structure-Activity RelationshipABSTRACT
The optimization of a series of 8-aza-quinazolinone analogs for antagonist activity against the CXCR3 receptor is reported. Compounds were optimized to avoid the formation of active metabolites and time-dependent-inhibitors of CYP3A4. In addition, antagonists showed potent against CXCR3 activity in whole blood and optimized to avoid activity in the chromosomal aberration assay. Compound 25 was identified as having the optimal balance of CXCR3 activity and pharmacokinetic properties across multiple pre-clinical species, which are reported herein.
Subject(s)
Quinazolines/chemical synthesis , Quinazolinones/chemical synthesis , Receptors, CXCR3/antagonists & inhibitors , Animals , Bleomycin/toxicity , Chromosome Aberrations , Cytochrome P-450 CYP3A , Cytochrome P-450 CYP3A Inhibitors , Dogs , Dose-Response Relationship, Drug , Drug Design , Humans , Inflammation , Inhibitory Concentration 50 , Leukocytes/drug effects , Macaca fascicularis , Mice , Models, Chemical , Quinazolines/pharmacology , Quinazolinones/pharmacology , Time FactorsABSTRACT
Eukaryotic mRNAs are appended at the 5' end, with the 7-methylguanosine cap linked by a 5'-5'-triphosphate bridge to the first transcribed nucleoside (m7GpppX). Initiation of cap-dependent translation of mRNA requires direct interaction between the cap structure and the eukaryotic translation initiation factor eIF4E. Biophysical studies of the association between eIF4E and various cap analogs have demonstrated that m(7)GTP binds to the protein ca. -5.0 kcal/mol more favorably than unmethylated GTP. In this work, a thermodynamic analysis of the binding process between eIF4E and several cap analogs has been conducted using Monte Carlo (MC) simulations in conjunction with free energy perturbation (FEP) calculations. To address the role of the 7-methyl group in the eIF4E/m7GpppX cap interaction, binding free energies have been computed for m(7)GTP, GTP, protonated GTP at N(7), the 7-methyldeazaguanosine 5'-triphosphate (m(7)DTP), and 7-deazaguanosine 5'-triphosphate (DTP) cap analogs. The MC/FEP simulations for the GTP-->m(7)DTP transformation demonstrate that half of the binding free energy gain of m(7)GTP with respect to GTP can be attributed to favorable van der Waals interactions with Trp166 and reduced desolvation penalty due to the N(7) methyl group. The methyl group both eliminates the desolvation penalty of the N(7) atom upon binding and creates a larger cavity within the solvent that further facilitates the desolvation step. Analysis of the pair m(7)GTP-m(7)DTP suggests that the remaining gain in affinity is related to the positive charge created on the guanine moiety due to the N(7) methylation. The charge provides favorable cation-pi interactions with Trp56 and Trp102 and decreases the negative molecular charge, which helps the transfer from the solvent, a more polar environment, to the protein.